Novo Nordisk stock soars after FDA approves first oral GLP-1 for weight loss [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
Food and Drug Administration approved the company's Wegovy pill as the first oral GLP-1 receptor agonist for weight management. The once-daily oral semaglutide 25 mg pill demonstrated a mean weight loss of 16.6% in the OASIS 4 trial when treatment was adhered to in adults with obesity or overweight with comorbidities. This weight loss is comparable to that achieved with injectable Wegovy 2.4 mg. One in three participants experienced 20% or greater weight loss during the trial. The FDA approval includes indications to reduce excess body weight, maintain weight reduction long-term, and reduce the risk of major adverse cardiovascular events. The pill's safety and tolerability profile was consistent with previous semaglutide trials for weight management. "The pill is here. With today's approval of the Wegovy pill, patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy injection," said Mike Doustdar, president and CEO of Novo No
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk [MSNBC.com]MSNBC.com
- FDA approves Wegovy pill for weight loss, the first daily oral medication of its kind [CBS News]CBS News
- FDA approves Wegovy weight loss pill from Novo Nordisk [MSNBC.com]MSNBC.com
- FDA approves Wegovy weight-loss pill from Novo Nordisk [USA TODAY]USA TODAY
- US regulators approve Wegovy pill for weight loss [Yahoo! Finance Canada]Yahoo! Finance Canada
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- NVO's page on the SEC website